Long-Term Follow-Up Study of Patients with Spinal Muscular Atrophy Receiving Risdiplam Treatment

Brief description of study

This study will evaluate the long-term safety and effectiveness of risdiplam (Evrysdi?), prescribed on the basis of the U.S. Package Insert (USPI) and clinician judgement, in adult and pediatric spinal muscular atrophy (SMA) patients.

Clinical Study Identifier: s22-00184
Principal Investigator: Mary-Lynn Y Chu.
Other Investigator: Patrick Kwon.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.